Abstract : High -throughput next-generation sequencing is a powerful tool to identify the genotypic landscapes of somatic variants and therapeutic targets in various cancers including gastric cancer, forming the basis for personalized medicine in the clinical setting. Although the advent of many computational algorithms leads to higher accuracy in somatic variant calling, no standard method exists due to the limitations of each method. Here, we constructed a new pipeline. We combined two different somatic variant callers with different algorithms, Strelka and VarScan 2, and evaluated performance using whole exome sequencing data obtained from 19 Japanese cases with gastric cancer (GC) ; then, we characterized these tumors based on identified driver molecular alterations. More single nucleotide variants (SNVs) and small insertions/deletions were detected by Strelka and VarScan 2, respectively. SNVs detected by both tools showed higher accuracy for estimating somatic variants compared with those detected by only one of the two tools and accurately showed the mutation signature and mutations of driver genes reported for GC. Our combinatorial pipeline may have an advantage in detection of somatic mutations in GC and may be useful for further genomic characterization of Japanese patients with GC to improve the efficacy of GC treatments.
INTRODUCTION
High-throughput next-generation sequencing (NGS), together with the development of powerful computational tools, has transformed biological and biomedical research, particularly cancer research, over the past several years. In a wide variety of tumor types, including gastric cancer (GC), the complex genotypic landscapes of somatic variants have been investigated (1 -3) . Most significantly, a number of clinically actionable mutations have been identified as therapeutic targets for cancer therapies, narrowing the gap between basic research and clinical application and forming the basis for personalized medicine in the clinical setting (4) .
During characterization of cancer genomes, calling somatic variations, mainly single nucleotide variants (SNVs) and small insertions/deletions (indels), by comparing a tumor sample with a matched normal sample is the critical step (5) . Although advances in NGS technologies and computational algorithms have led to higher accuracy in somatic variant calling, this step is still difficult due to low allele frequencies, low sample purity, clonal heterogeneity, inadequate sequencing coverage, sequencing errors, and ambiguities in short read mapping (6) . To meet the challenges of somatic variant calling, a number of tools with enhanced accuracy have been developed that compare a tumor!normal pair directly at each locus of a possible variant (7) . Although each new tool has been compared with some earlier applications (8) , the accuracy of the combination methods using multiple tools and their relative advantages in real applications are largely unknown.
GC is a leading cause of global cancer mortality, with high incidence rates in Asia, including Japan (9) . Recent genome sequencing studies have provided valuable insights into the key genetic alterations of GC, resulting in identification of its major driver genes (10) (11) (12) (13) (14) . However, potential genomic alterations among Japanese individuals are not well understood, although several studies identified the potential mutations in specific subtypes of GC, such as diffuse-type (13) and mucinous GCs (14) . Recent reports from The Cancer Genome Atlas (TCGA) research network and the Asian Cancer Research Group (ACRG) explored the molecular landscape of GC based on genetic/epigenetic and genetic profiles of GCs, respectively (3, 15) , and provided four subtypes in each group. These two classifications showed differences at least partially explained by the difference in ethnic origin of the patients : patients from USA and Western Europe in the TCGA and those from Korea in the ACRG (16) . Therefore, further analyses clarifying the molecular landscape of GC in Japanese populations is still needed.
For further detailed exploration of the genetic basis of GC in Japanese individuals, somatic variant detection methods with higher performance compared with frequently used somatic variant calling tools are necessary. Herein, we constructed a new pipeline. We combined two somatic variant callers with different algorithms, Strelka (17) and VarScan 2 (18) , and evaluated the performance of this newly constructed method using whole exome sequencing data obtained from 19 Japanese cases with GC ; then, we characterized these tumors based on identified driver molecular alterations.
ORIGINAL
Construction of a combinatorial pipeline using two somatic variant calling methods for whole exome sequence data of gastric cancer
MATERIALS AND METHODS

Patients and DNA samples
Frozen GC samples and paired non-tumorous gastric tissues were obtained from 19 patients with histologically proven primary GC who underwent gastrectomy at the Kyoto Prefectural University of Medicine Hospital (Kyoto, Japan) between 2013 and 2014 (Table 1) . None had synchronous or metachronous multiple cancers in other organs. Relevant clinical data were available for all patients. The pathological classification of tumors was determined according to UICC classification (19) . Of 19 cases, 12 and 5 cases were differentiated and undifferentiated GCs, respectively. The study was performed according to the Declaration of Helsinki protocols. Formal written consent was obtained from all patients after the local ethics committee (Kyoto Prefectural University of Medicine and Tokushima University) approved all aspects of these studies. Epstein!Barr virus (EBV)-associated GC (EBVaGC) was determined by in situ hybridization (ISH) of EBV-encoded small RNAs as described elsewhere (20) . Genomic DNA from the cancerous or paired non-tumorous gastric tissues was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocols.
Exome sequencing
A flow chart for exome sequencing and data processing is shown in Figure 1 . Exome capture was performed using the Truseq DNA Sample Prep Kit (Illumina, San Diego, CA) or SureSelect XT Human All Exon Kit V5 (Agilent Technologies, Santa Clara, CA). Libraries were sequenced using the HiSeq 1500 or 2500 platform (Illumina) with 101 -bp paired-end reads. Image analysis and base calling were performed using HiSeq Control Software v2.2.38 (Illumina), Real Time Analysis v1.18.61 (Illumina), and bcl2fastq Conversion Software v1.8.4 (Illumina). Reads were quality -filtered using a FASTX Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) and were aligned to the human genome sequence assembly hg19 (GRCh37) using the Burrows-Wheeler Alignment tool v0.7.12 (21) . The alignments were converted from a sequence alignment map format to sorted and indexed binary alignment map (BAM) files, and duplicated reads were removed using SAMtools v0.1.19 and v1.2 (22) . Local realignments around indels and base quality score recalibration were performed using the Genome Analysis Toolkit version 3.3-0 (23). A summary of exome sequence performance is shown in Table 2 . To perform the SNV analysis, pileup files were created from the alignment map files by SAMtools and applied to the two somatic variant calling tools, VarScan 2 v2.3.7 and/or Strelka v1.0.14. SNVs were identified by VarScan 2, filtered with minor allele frequency "0.05 from the paired non-tumorous tissues, and were considered significant at P ! 0.05 by Fisher's exact test. Variants that passed the filters were annotated using ANNOVAR ver 2015March (24) . To detect somatic copy number variations (CNVs), we applied VarScan 2 to the pileup map files as follows : 1) log coverage ratios were calculated to compare the GC tissues with paired non-tumorous tissues and 2) regions with CNVs were detected using circular binary segmentation with DNAcopy (R /Bioconductor). The relatives were adjusted by the median of each paired sample, and determined as amplification (log2 ratio"2) or deletion (log2 ratio!0.5).
Global methylation analysis
Bisulfite conversion of DNA was conducted using the EZ DNA Methylation Gold Kit (Zymo Research, Irvine, CA, USA). According to the manufacturer's instructions, HumanMethylation450K BeadChip (Illumina) analysis was performed on 16 cases whose genomic DNA were available for analysis. The default settings of GenomeStudio Software's DNA methylation module (Illumina) were applied to calculate the methylation levels of CpG sites as β- The gray shaded area shows samples analyzed using Truseq Exome Kit (Illumina) and Hiseq 1500 sequencer (n = 6). values [β = intensity (methylated)/intensity (methylated + unmethylated)]. The data were further normalized using a peak correction algorithm embedded in the R-package of Illumina Methylation Analyzer (25) . Averaged β-difference in CpG island-based regions of the MLH1 gene was calculated based on a β-difference matrix in which β-values of paired non-tumorous gastric tissues were subtracted from those of tumors.
RESULTS
Classification and comparison of variants categorized by two different tools
A total 7046 and 4896 SNVs and 795 and 1446 indels were detected by Strelka and VarScan 2, respectively, suggesting that SNVs were better detected by Strelka than VarScan 2, whereas indels were better detected by VarScan 2 than Strelka ( 
Mutation signature of GC
Mutations in human cancer, including GC, are classified into various mutational signatures using base substitution patterns and information of the trinucleotide context of each mutation. There are six classes of base substitutions : C!A, C!G, C!T, T!A, T!C, and T!G. C!T substitution at either NpCpG or TpCpN trinucleotide has been reported as the predominant mutation in GC (26) . The cause of increasing C!T substitution is considered to be agerelated relatively elevated spontaneous deamination of 5 -methylcytosine (NpCpG) or over-activation of the APOBEC family of cytidine deaminases (TpCpN) (27, 28) . We classified variants in category III using Maftools (https://github.com/PoisonAlien/ maftools), and detected the feature of increasing C!T substitution at NpCpG or TpCpN in our cases of GC (Figure 3 ).
Characterization of genomic features in GC
To characterize genomic features of 19 GCs, we first compared the number of somatic SNVs and indels as well as genes with somatic CNVs in each case. Three cases (cases2, 19, and 3) showed higher numbers of SNVs and indels compared with others (Figure 4A) , and hypermethylation of MLH1 was observed in two of those cases (cases 2 and 3 ; Figure 4B ). Four cases (cases 17, 13, 10, and 4) showed higher number of genes with CNVs ( Figure 4C ), and mutations in TP53 were observed in three of those cases.
The TCGA research network, ACRG, and others reported alterations of various driver genes and therapeutic targets in GC, such as TP53, cell cycle mediators, genes related to receptor tyrosine kinases (RTKs), RAS and PI(3) -kinase (RAS-PI3K) signaling, and the DNA mismatch repair (MMR) system (3, 15) . Therefore, we next focused on those driver alterations ( Figure 5 ). As with TCGA and ACRG, TP53 was detected as the most frequently altered gene (13/19, 68%). Amplification of CCND1 and a loss-of-function mutation of CDKN2A in cell cycle mediators were observed. In RTKs and the RAS-PI3K signaling pathway, activating alterations (gain-offunction mutations and amplifications) were observed in ERBB2, PIK3CA, KRAS, EGFR, and FGFR2, and loss-of-function mutations were observed in PTEN.
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DISCUSSION
It is challenging for a somatic variant calling tool to balance between detecting true low-allelic somatic variants and reducing the number of false positive calls. Sensitivity, specificity, and accuracy have been discussed for various somatic variant calling tools (6, 29 -31) . The calling algorithms of Strelka and VarScan 2 used in this research are different from each other, with each tool having unique features. Strelka uses a complex set of calculations based on a Bayesian approach, wherein the tumor and normal allele frequencies from realigned BAM files are treated as continuous values (17) . VarScan 2 applies Fisher's exact test to the tumor and normal allele frequencies obtained from a pileup file (18) . Strelka identifies low-allelic-fraction candidate mutations with high sensitivity, whereas VarScan 2 detects little low-allelic-fraction candidates (6, 29) . Therefore, tumor purity has a relatively higher impact on the numbers of variants detected by VarScan 2. In the present study, SNVs were better detected by Strelka than VarScan 2 (Figure 2 A), suggesting that our GC tumor samples had a relatively low degree of purity. Notably, more indels were detected by VarScan 2 ( Figure 2B ) because Strelka filtered out indels in microsatellites and tandem repeats (17) . This effect showed higher impact on MSI samples (Table 3) . Therefore, SNVs and indels are preferably evaluated by Strelka and VarScan 2, respectively, for the genetic characterization of GC. Conversely, variants in category III (detected by both Strelka and VarScan 2) showed a higher overlapping rate with COSMIC and a lower overlapping rate with dbSNP, compared with other categories. Therefore, the highest accuracy for estimating variants can be obtained using both Strelka and VarScan 2. Using variants in category III, we found that mutation signatures in Japanese GC cases were the same as the previously reported signatures of GC using the data from TCGA and the International Cancer Genome Consortium, which contains Japanese cases (26) . This result indicates that (i) variants in category III of our approach have accuracy sufficient to categorize mutation signatures in GC and (ii) C!T substitution at NpCpG or TpCpN trinucleotide is the predominant mutation in GC regardless of ethnicity or race.
The TCGA research network reported that GC could be classified into four molecular subtypes : EBV-positive (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CIN) (3). In the EBV-positive subtype, frequent PIK3CA mutation and DNA promoter hypermethylation were reported. In our cases, however, neither PIK3CA mutation (Figure5) nor DNA hypermethylation pattern (data not shown) was observed. ACRG provided four different subtypes : tumors with microsatellite instability (MSI), tumors with epithelial-mesenchymal transition (EMT), tumors with microsatellite stability and p53 activity (MSS/TP53 + ), and tumors with microsatellite stability and loss of p53 activity (MSS/TP53 -) (15) . In those subtypes, MSS/TP 53 + showed the highest frequency of EBV positivity. However, 5 of 13 cases with the TP53 mutation and 3 of 6 cases without the TP53 mutation showed EBV positivity. These results suggested that genomic features of GC may be different between Japanese patients and other patients from different ethnic origins, such as the USA and Western Europe in the TCGA and Korea in the ACRG. Thus, further characterization of GC in Japanese patients remains to be performed for identifying bona fide molecular targets and developing solid therapeutic approaches.
In conclusion, we constructed a combinatorial pipeline using two different somatic variant calling methods, which may be useful for accurately detecting mutations in GC. Personalized medicine for Japanese patients with GC needs accurate and detailed molecular characteristics of this disease to provide tailored patient treatments. Genomic characterization through application of our pipeline to larger cohorts of Japanese patients is expected be useful to improve the efficacy of GC treatments.
